Shares of Eli Lilly and Co. and Johnson & Johnson fell on Wednesday following a study in which a cheap older generic schizophrenia drug was about as effective as Lilly’s costly Zyprexa treatment.
Shares of Eli Lilly and Co. and Johnson & Johnson fell on Wednesday following a study in which a cheap older generic schizophrenia drug was about as effective as Lilly’s costly Zyprexa treatment.